The Shelved Promise: Ebola Vaccine for Bundibugyo Strain Awaits Deployment for 15 Years

A highly effective vaccine for the deadly Bundibugyo strain of Ebola has remained on the shelf for 15 years, despite a severe outbreak currently ravaging parts of Central and East Africa, particularly the Democratic Republic of Congo and Uganda. This critical delay highlights a significant challenge in global public health: the gap between scientific breakthrough and widespread deployment. Virologist Thomas Geisbert, whose team developed this promising candidate, expressed frustration as hundreds are infected and around 200 have died in the ongoing crisis. The vaccine's efficacy was unequivocally demonstrated in 2011 through a study involving crab-eating macaques. Monkeys infected with the Bundibugyo strain, but previously vaccinated, exhibited no symptoms, while two-thirds of their unvaccinated counterparts succumbed to the aggressive virus, experiencing fever, weight loss, and severe bleeding. Geisbert's rVSV (recombinant vesicular stomatitis virus) vaccine utilizes a harmless virus to deliver genetic instructions, enabling the body to combat the disease. Despite these compelling results, the vaccine has not progressed to human trials, a process that could take months even as the virus causes widespread suffering. Geisbert's journey began in the early 2000s, initially funded by the US Army as a defense project to counter potential biological weapons threats post-9/11. His early work led to a breakthrough in 2003, showing a single injection could protect monkeys from other Ebola strains. However, when he published these findings, commercial interest was virtually nonexistent. "There just wasn't a global market for an ebola vaccine," Geisbert noted, explaining that it wasn't seen as a "moneymaker," deterring pharmaceutical companies from investing in its development and mass production. Interest in Ebola vaccines reached a critical mass during the devastating 2013-2016 epidemic of the Zaire strain in West Africa, which infected 28,600 people and claimed 11,300 lives. This crisis spurred a global race for a vaccine, leading to the development and deployment of Merck's Ervebo vaccine, partly based on Geisbert's foundational research. This success earned him recognition as one of Time magazine's "Ebola fighters." However, Geisbert's initial focus omitted the Bundibugyo strain, primarily because it had historically caused fewer and less fatal outbreaks, leading to the assumption it was "least likely to pop up." "We guessed wrong," Geisbert admitted, reflecting on the current Bundibugyo outbreak. Concerned by this knowledge gap, he modified a vaccine in 2011, leading to the successful macaque study. Now, with the current outbreak rivaling the scale of the 2013-2016 epidemic, efforts to accelerate vaccine deployment are intensifying. The World Health Organization (WHO) has identified Geisbert's rVSV Bundibugyo vaccine as the most promising candidate, likely due to its similarity to the successful Ervebo vaccine and the proven efficacy of rVSV-based vaccines in ring vaccination strategies, as demonstrated in a 2023 study for Bundibugyo and a 2025 trial for the Sudan strain. The persistent challenge remains the financial viability of such vaccines. As Courtney Woolsey, a co-author on the 2023 study, highlighted, "Nobody really makes money off these vaccines, so there are funding barriers." This commercial disinterest leaves critical public health tools languishing. While the nonprofit Coalition for Epidemic Preparedness Innovations (CEPI) has offered some funding to prepare and test the necessary materials, the 15-year delay underscores a systemic failure to prioritize potential life-saving interventions for diseases that primarily affect vulnerable populations, demanding a re-evaluation of global health investment strategies.